What Happened?
Boston, MA-based TransCode Therapeutics Promoted Zdravka Medarova as Chief Technology Officer
Date of management change: September 30, 2021
Boston, MA-based TransCode Therapeutics Promoted Zdravka Medarova as Chief Technology Officer
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.
Zdravka Medarova is Chief Technology Officer at TransCode Therapeutics. Previously, Zdravka held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Ramachandran Vishnu, Thakur Satyendra, Anutooshkin Gord, Seaman Patrick, Hepworth Ian, Valencia William, Chang Welton, Osborne Alan, Collier George, Smith Joelle, Sanzoterra Teresa
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.